Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials
@article{Bates2011TreatmentEO, title={Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials}, author={D. Bates}, journal={Neurology}, year={2011}, volume={76}, pages={S14 - S25} }
Intervention with interferon-β (IFNβ) therapy counters early inflammatory damage to myelin and protects axons; such therapy might demonstrate greater efficacy earlier in the disease course compared with later when permanent damage has already occurred. Clinical trials conducted in patients with clinically isolated syndrome (CIS) show clinical benefits of early treatment of multiple sclerosis (MS), as evidenced by delayed conversion to clinically definite multiple sclerosis and reduced… CONTINUE READING
Figures, Tables, and Topics from this paper
Paper Mentions
Interventional Clinical Trial
Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived
cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via… Expand
Conditions | Autoimmune, Multiple Sclerosis |
---|---|
Intervention | Device, Procedure |
85 Citations
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
- Medicine
- Multiple sclerosis and related disorders
- 2016
- 13
- Highly Influenced
Cladribine in multiple sclerosis: pitfalls in a new treatment landscape
- Medicine
- Expert opinion on pharmacotherapy
- 2013
- 4
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
- Medicine
- Journal of Neurology, Neurosurgery & Psychiatry
- 2016
- 32
- PDF
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
- Medicine
- Clinical therapeutics
- 2012
- 19
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort
- Medicine
- Clinical Neurology and Neurosurgery
- 2012
- 21
Multiple sclerosis: Therapeutic applications of advancing drug delivery systems.
- Medicine
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- 2017
- 30
Multiple sclerosis: effect of beta interferon treatment on survival.
- Medicine
- Brain : a journal of neurology
- 2019
- 10
- PDF
Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis.
- Medicine
- Multiple sclerosis and related disorders
- 2012
- 3
- Highly Influenced
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
- Medicine
- Nature Reviews Neurology
- 2019
- 32
References
SHOWING 1-10 OF 57 REFERENCES
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
- Medicine
- Annals of neurology
- 1996
- 2,356
- PDF
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
- Medicine
- Neurology
- 2006
- 467
- PDF
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
- Medicine
- The New England journal of medicine
- 2000
- 1,438
- PDF
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
- Medicine
- Neurology
- 1997
- 217
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
- Medicine
- The Lancet
- 2001
- 1,003
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
- Medicine
- The Lancet
- 1998
- 764